Clinical Trial Update: A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A multi-center, single-arm Phase I/IIa clinical trial evaluating EBViNT cell therapy for EBV-positive malignancies after treatment failure; current status is UN…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebv-associated Extranodal Nk T-cell Lymphoma
• Ebv-associated Gastric Carcinoma or Esophageal Adenocarcinoma

Drugs mentioned

• EBViNT cell (EBV Specific Autologous CD8+ T Cell) (EBViNT cell)

Snippet

Sponsor: Eutilex | Conditions: EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma | Phase 1, Phase 2 | Status: UNKNOWN